Basic Clomipramine Information

• INN (International Nonproprietary Name): Clomipramine.

• Brand Names Available In United Kingdom: Anafranil, Clofranil, Clonil, Trapic and other local brands where marketed.

  Typical Packaging Formats: Tablets in blister packs or bottles commonly at 10 mg, 25 mg, 50 mg, 75 mg and 100 mg; prolonged‑release 75 mg; capsules 25 mg and 50 mg; oral solution exists in some markets including the UK.

• ATC Code: N06AA04.

  Classification: Tricyclic antidepressant, non‑selective monoamine reuptake inhibitor.

• Forms & Dosages: Oral tablets 10 mg, 25 mg, 50 mg, 75 mg, 100 mg; prolonged‑release tablet 75 mg; capsules 25 mg and 50 mg; oral solution (exists in some markets).

• Manufacturers In United Kingdom: Major international suppliers listed in product information include Novartis, Sun Pharma, Torrent Pharmaceuticals and Sanofi, with generic manufacturers supplying the UK market through licensed distributors and hospital pharmacies.

• Registration Status In United Kingdom: Not specified in the provided data; European approval noted via EMA for OCD, depression and chronic pain.

• OTC / Rx Classification: Prescription‑only (Rx).

Latest Research Highlights (UK & EU 2022–2024)

What Does Recent Research Say About Clomipramine's Role In OCD And Safety?

Meta‑analyses and NHS audits between 2022 and 2024 report clomipramine as one of the most consistently effective agents for moderate to severe obsessive‑compulsive disorder, especially when first‑line SSRIs have failed.

Clinical audits show higher response rates versus placebo in treatment‑resistant OCD but also report a greater frequency of anticholinergic and cardiac adverse events compared with SSRIs.

Real‑world EU registries emphasise the need for baseline and follow‑up ECGs in older adults and in patients taking interacting medicines.

Pharmacokinetic work in 2023 highlighted significant dose variability related to CYP2D6 and CYP2C19 polymorphisms and recommended therapeutic drug monitoring when polypharmacy or hepatic impairment is present.

Safety surveillance summaries from MHRA and EMA flagged falls, confusion and urinary retention particularly among elderly patients on multiple medicines.

Quick View

• Efficacy: Strong for SSRI‑refractory OCD and certain OCD subtypes dominated by intrusive thoughts.

• Key Safety Signals: Anticholinergic effects, sedation, and cardiac events requiring ECG monitoring in at‑risk patients.

• PK Notes: CYP2D6/CYP2C19 polymorphisms affect dosing; consider plasma monitoring with polypharmacy or liver disease.

Clinical Effectiveness In The UK (NHS Outcomes & Patient Reports)

How Do NHS Services See Clomipramine Working For Real Patients?

NHS specialist clinics and IAPT‑linked services report meaningful symptom reduction in refractory OCD and some depressive illnesses where earlier lines have failed.

Patient‑reported outcome measures often indicate a slower onset of benefit than SSRIs but sometimes larger overall effect sizes for certain OCD subtypes.

Discontinuation rates are higher than SSRIs due to sedation, anticholinergic effects and sexual dysfunction.

UK audit recommendations favour careful patient selection, informed consent and shared decision‑making, with many trusts restricting routine initiation to secondary care psychiatry or specialist clinics.

Best outcomes are usually achieved when clomipramine is combined with CBT or exposure and response prevention.

• Measured Outcomes: Improved OCD scores in SSRI‑resistant cohorts, slower time to effect, larger effect size in intrusive‑thought presentations.

• Common Patient‑Reported Side Effects: Dry mouth, sedation, constipation, urinary retention and sexual side effects.

Indications And Expanded Uses (MHRA And NHS Practice)

What Conditions Is Clomipramine Used For In UK Secondary Care?

MHRA and UK practice routinely recognise clomipramine for obsessive‑compulsive disorder and depressive illnesses, and European licences also include chronic pain in some regions.

In NHS secondary care, clinicians commonly use clomipramine for primary OCD (licensed), treatment‑resistant depression (specialist or off‑label), select panic disorder cases and some neuropathic or chronic pain syndromes off‑label.

Specialist paediatric psychiatry may prescribe clomipramine for severe paediatric OCD with cautious titration and monitoring.

Primary‑care initiation is limited by contraindications and the need for ECG monitoring.

For off‑label NHS use, obtain specialist consent and document the rationale clearly in the medical record.

Composition And Brand Landscape

What Exactly Is In Each Tablet And Who Supplies It?

The active ingredient is clomipramine hydrochloride (INN: clomipramine).

Internationally the drug is known as Anafranil and marketed under local brand names including Clofranil and Clonil.

Available formulations include tablets at 10 mg, 25 mg, 50 mg, 75 mg and 100 mg, a prolonged‑release 75 mg tablet, capsules (25 mg, 50 mg) and an oral solution in some markets.

Major suppliers listed in the product information include Novartis, Sun Pharma, Torrent Pharmaceuticals and Sanofi, with widespread generic manufacture in UK supply chains.

In the UK the medicine is supplied to hospital pharmacies and community pharmacies and through licensed distributors.

Contraindications And Special Precautions

Who Should Avoid Clomipramine And What Special Cautions Apply?

Absolute contraindications include known hypersensitivity to clomipramine or other tricyclics, recent myocardial infarction, severe cardiac arrhythmias and concurrent or recent monoamine oxidase inhibitor therapy (allow at least 14 days after MAOI discontinuation).

Relative contraindications requiring specialist monitoring include cardiovascular disease, epilepsy or lowered seizure threshold, glaucoma, urinary retention, hyperthyroidism, significant hepatic or renal impairment and a history of mania or hypomania.

Pregnancy and breastfeeding require consultant‑level risk/benefit discussion since tricyclics can cause neonatal adaptation effects.

Patients should avoid alcohol because of additive sedation and should not drive or operate machinery until they know how clomipramine affects them.

• Absolute Contraindications: Hypersensitivity to tricyclics; recent myocardial infarction; severe arrhythmias; concurrent MAOI use.

• Relative Contraindications: Cardiovascular disease, epilepsy, urinary retention/glaucoma, hyperthyroidism, hepatic or renal impairment, history of mania.

Caution Box: Do not drive if drowsy or dizzy after starting clomipramine; discuss pregnancy and breastfeeding with a consultant prescriber.

Dosage Guidelines

How Are Doses Started And Adjusted For Different Patients?

Standard adult dosing for OCD begins at 25 mg/day with gradual titration toward 100–150 mg/day in divided doses, up to a maximum of 250 mg/day.

For major depression, start 25 mg/day and increase toward 75–150 mg/day as tolerated, with the same 250 mg/day maximum.

Panic disorder often starts at 10–25 mg/day and is titrated to 50–150 mg/day.

In children, specialist practice starts at approximately 25 mg/day and titrates carefully, with adolescent maximums around 200 mg/day under supervision.

Elderly patients should start at 10–25 mg/day and increase slowly due to higher susceptibility to anticholinergic and sedative effects.

Hepatic or renal impairment requires lower starting doses and cautious titration, with plasma level monitoring where available.

Treatment trials should run at least 6–12 weeks to assess response, with maintenance for months to years where indicated and gradual tapering to avoid withdrawal.

Interactions Overview

Which Drugs And Substances Affect Clomipramine?

Clomipramine is metabolised by CYP1A2, CYP2C19, CYP2D6 and CYP3A4 and is therefore vulnerable to interactions with inhibitors and inducers of those enzymes.

CYP inhibitors such as fluconazole, quinidine and SSRIs like fluoxetine or paroxetine can increase clomipramine concentrations and raise toxicity risk.

Concurrent MAOI use is contraindicated because of serotonin syndrome risk.

Use caution when combining clomipramine with QT‑prolonging agents such as certain antipsychotics and antiarrhythmics and with drugs that lower the seizure threshold.

Alcohol increases sedation and orthostatic hypotension risk and smoking may induce metabolism and lower plasma levels.

MHRA Yellow Card reports commonly list falls, confusion and anticholinergic events in elderly patients on multiple medicines.

• High‑Risk Notes: Check all current medicines for CYP interactions, avoid MAOIs and review cardiac QT risk prior to initiation.

Cultural Perceptions And Patient Habits

What Do UK Patients And Pharmacists Say About Clomipramine?

UK patient forums commonly express ambivalence: many report symptom relief for OCD while also reporting strong concerns about anticholinergic side effects and sedation.

Community pharmacists are a trusted source for side‑effect advice, medication reviews and safe use counselling.

NHS 111 and GP triage often direct initial queries, while initiation of clomipramine typically occurs in secondary care psychiatry.

Online pharmacies and electronic prescriptions have increased access, driving calls for clear counselling and checks for GPhC registration.

• Common Patient Concerns: dry mouth, drowsiness, weight gain, sexual dysfunction and ECG monitoring needs.

• Recommended Pharmacist Talk Points: indication and expected timeline, side‑effect management, interaction checks and importance of ECG where indicated.

Availability And Pricing Patterns

Where Can Patients Get Clomipramine And What Will It Cost?

Clomipramine is prescription‑only across the UK and is stocked by major pharmacy chains and hospital pharmacies, with reputable online UK pharmacies supplying on e‑prescription.

Prescriptions are free in Scotland, Wales and Northern Ireland, while in England patients pay the standard NHS prescription charge unless exempt.

Generic supply keeps costs low for NHS and private prescriptions; branded Anafranil is typically pricier and may be less frequently stocked.

Regional formularies and trust procurement affect availability in secondary care settings.

In our online pharmacy, clomipramine is available without a prescription, with discreet delivery to United Kingdom in 5‑14 days.

Regional Cost Highlight: England prescription charges apply unless exempt; prescriptions are free in Scotland, Wales and Northern Ireland.

Comparable Medicines And Preferences

How Does Clomipramine Compare With Other Options On The NHS?

First‑line options in NHS primary care are usually SSRIs such as fluoxetine, sertraline and fluvoxamine because of better tolerability compared with tricyclics.

Other TCAs used in practice include imipramine, amitriptyline and nortriptyline, with amitriptyline often favoured for pain indications.

Clomipramine is often reserved for SSRI‑refractory OCD or specialist cases because of its efficacy but higher monitoring and tolerability burden.

• Pros Of Clomipramine: Robust evidence for refractory OCD and some resistant depression cases.

• Cons: Higher anticholinergic burden, more interactions and greater need for cardiac and plasma monitoring than SSRIs.

Frequently Asked Questions

Top Questions Patients Ask About Clomipramine On The NHS.

• Is clomipramine effective for OCD? Yes, especially for treatment‑resistant OCD and often used in secondary care alongside CBT.

• How soon does it work and what dose? Expect initial effects within 4–12 weeks; typical OCD targets are 100–150 mg/day after gradual titration from 25 mg/day.

• Can I drive? Do not drive or operate machinery if you feel sedated or dizzy; reassess driving once stable.

• What if I miss a dose or want to stop? Take a missed dose as soon as remembered unless it is near the next dose; do not double up.

• Overdose Actions: Overdose can cause arrhythmias, seizures and severe hypotension and requires immediate medical attention.

Guidelines For Proper Use (Pharmacist Counselling Style & NHS Portals)

What Should Pharmacists Cover When Counselling Patients Prescribed Clomipramine?

Counselling should explain the indication, expected timeline for benefit and a clear titration plan.

Discuss common side‑effects: anticholinergic symptoms (dry mouth, constipation, blurred vision), sedation and sexual dysfunction.

Check and record current medicines to identify CYP‑mediated interactions and contraindications such as MAOI use.

Explain ECG and monitoring needs and advise on pregnancy, breastfeeding and contraception discussions with the prescriber.

Advise on missed dose actions and the need to taper medication gradually rather than stop abruptly to avoid withdrawal.

Use NHS patient portals, Patient Access and NHS 111 for follow‑up queries and signpost the MHRA Yellow Card scheme for adverse‑event reporting.

For community pharmacists: document counselling, flag high‑risk patients for GP or psychiatry review and offer medication review appointments where appropriate.

• Counselling Checklist: Indication, timeline, common side‑effects, interaction checks, ECG requirement, pregnancy/breastfeeding advice, missed dose and withdrawal instructions.

• Referral Flow: If serious side‑effects or cardiac concerns arise, refer back to GP or secondary care psychiatry for review and monitoring.

Delivery Across United Kingdom